The 2013 Low Dose Colchicine (LoDoCo) trial, the Colchicine Cardiovascular Outcomes (COLCOT) trial, and the LoDoCo 2 trial have demonstrated that treatment with colchicine for secondary prevention resulted in a reduction in future ASCVD events.17, 18, 19 Given the role of the NLRP3 inflammasome in both ASCVD and AF, we review the current evidence evaluating the role of anti-inflammatory therapies for treatment and prevention of AF. The gene discussed is NLRP3; the disease is atherosclerosis.